To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses here.

Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA

Ending of the PHE: Overview & Implications for Surveillance, Infection Prevention & Control 
Brendan Jackson, MD, MPH
CDR, U.S. Public Health Service
COVID-19 Response Clinical Team, Late Sequelae Unit
U.S. Centers for Disease Control and Prevention

Michael Stevens, MD, MPH, FSHEA, FIDSA, FACP 
System Healthcare Epidemiologist
Associate CQO for Infection Prevention & Antimicrobial Stewardship
WVU Health System 
Professor of Internal Medicine & Public Health, WVU

Availability and Commercialization of COVID Vaccines and Treatment
Meghan E. Pennini, PhD
Director, Therapeutics 
HHS Coordination Operations and Response Element (H-CORE) 
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services

Moving from Emergency Use Authorization to Approval of COVID-19 Treatments: Paxlovid Update
John Farley, MD, MPH
Director, Office of Infectious Diseases 
Office of New Drugs, Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Q&A and Discussion 
All panel members plus:
Alex J. Kallen, MD, MPH 
Chief, Prevention and Response Branch
Division of Healthcare Quality Promotion
U.S. Centers for Disease Control and Prevention